Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year.
Many, but not all patients experience weight gain 1 year after a breast cancer diagnosis; clearly defined, clinically relevant groups at risk of weight gain have yet to be described. We set out to determine the factors associated with weight gain over time in patients with invasive breast cancer dur...
| Publicado en: | Breast Journal Vol. 13; no. 3; pp. 258 - 266 |
|---|---|
| Autores principales: | , , |
| Formato: | research Journal Article |
| Publicado: |
Wiley-Blackwell
May/Jun2007
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105731124&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105731124 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1075122X ET6 jtl: Breast Journal issn: 1075122X maglogo: Y pubinfo: dt: May/Jun2007 vid: 13 iid: 3 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 105731124 105731124 2009630198 10.1111/j.1524-4741.2007.00419.x NLM17461900 105731124 ppf: 258 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year. aug: au: Makari-Judson G Judson CH Mertens WC affil: Comprehensive Breast Center and Baystate Regional Cancer Program, Springfield, Massachusetts 01107, USA. grace.makari-judson@bhs.org sug: subj: Breast Neoplasms Diagnosis Breast Neoplasms Drug Therapy Weight Gain Adult Antineoplastic Agents Adverse Effects Antineoplastic Agents, Combined Adverse Effects Body Mass Index Breast Neoplasms Surgery Chemotherapy, Adjuvant Adverse Effects Female Middle Age Multivariate Analysis Obesity Etiology Prospective Studies Questionnaires Regression Risk Factors Human Adult: 19-44 years Middle Aged: 45-64 years Female ab: Many, but not all patients experience weight gain 1 year after a breast cancer diagnosis; clearly defined, clinically relevant groups at risk of weight gain have yet to be described. We set out to determine the factors associated with weight gain over time in patients with invasive breast cancer during a period of predominantly anthracycline-based adjuvant chemotherapy and to identify groups with differing weight gain risks. Breast cancer patients (stage I-IIIB) were identified in a retrospective chart review. Evaluated parameters included weight at diagnosis and 1, 2, and 3 years later, height, body mass index (BMI), age, menopausal and change in menopausal status, as well as therapy and pathologic stage. Regression models identified significant independent predictors of weight change. Recursive partitioning analysis (RPA) was employed to divide the dataset into relevant and significant groups. In 185 identified patients, regression models and RPA demonstrated that weight gain at 1 year was associated with younger age, adjuvant chemotherapy, and lower BMI. Weight gain at 2 years (n = 176) was greater than at year 1, and in addition to weight gain at year 1, was associated with younger age and adjuvant chemotherapy in regression analysis; RPA found that anthracycline therapy, age, and BMI were important. Weights at 3 years were similar to those seen at 2 years. Early-stage breast cancer patients treated with chemotherapy continue to gain weight 2 years after diagnosis, and this weight gain appears to be persistent at year 3. Observation beyond 1 year is needed to adequately evaluate weight gain in early-stage breast cancer patients, particularly for those receiving contemporary adjuvant chemotherapy. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|